Literature DB >> 18665399

Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design.

Abhay T Sangamwar1, Leena B Labhsetwar, Sharad V Kuberkar.   

Abstract

Microsomal cytochrome P450 family 1 enzymes has great importance in the bioactivation of mutagens. P450 catalyzed reactions involve a wide range of substrates, and this versatality is reflected in a structural diversity, evident in the active sites of available P450 structures. This structure offers a template to study further structure-function relationships of alternative substrates and other cytochrome P450 family 1 members. In this paper, we document a homology model of CYP P450 1A1 from Homo sapiens, developed on the basis of template crystal structure of human microsomal P450 1a2 in complex with inhibitor (PDB Id: 2HI4). Homology modeling is performed at the programs, both in the commercial and public realms. We tried to explore CYP1A1 as a potential target for anticancer chemotherapy. To gain an insight into the binding of ligands with enzyme, protein-ligand complex was developed by including information about the known ligand as spatial restraints and optimizing the mutual interactions between the ligand and the binding site. Active site characterization and the study for involvement of specific aminoacids in binding with ligand, facilitates structure based inhibitor design. This study should prove useful in the design and development of potential novel anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18665399     DOI: 10.1007/s00894-008-0354-4

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  41 in total

1.  Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein.

Authors:  I Muegge; Y C Martin; P J Hajduk; S W Fesik
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

2.  The penultimate rotamer library.

Authors:  S C Lovell; J M Word; J S Richardson; D C Richardson
Journal:  Proteins       Date:  2000-08-15

Review 3.  Protein structure computing in the genomic era.

Authors:  T Schwede; A Diemand; N Guex; M C Peitsch
Journal:  Res Microbiol       Date:  2000-03       Impact factor: 3.992

4.  An overview of structural genomics.

Authors:  S K Burley
Journal:  Nat Struct Biol       Date:  2000-11

5.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

6.  Cell-specific regulation of human CYP1A1 and CYP1B1 genes.

Authors:  S Kress; W F Greenlee
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 7.  Protein structure--based drug design.

Authors:  P J Whittle; T L Blundell
Journal:  Annu Rev Biophys Biomol Struct       Date:  1994

8.  Evaluation of docking/scoring approaches: a comparative study based on MMP3 inhibitors.

Authors:  S Ha; R Andreani; A Robbins; I Muegge
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

9.  Prediction of the three-dimensional structure of human interleukin-7 by homology modeling.

Authors:  R T Kroemer; S W Doughty; A J Robinson; W G Richards
Journal:  Protein Eng       Date:  1996-06

10.  Molecular modeling study of the editing active site of Escherichia coli leucyl-tRNA synthetase: two amino acid binding sites in the editing domain.

Authors:  Keun Woo Lee; James M Briggs
Journal:  Proteins       Date:  2004-03-01
View more
  1 in total

Review 1.  Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.

Authors:  Zbigniew Dutkiewicz; Renata Mikstacka
Journal:  Bioinorg Chem Appl       Date:  2018-07-25       Impact factor: 7.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.